APA (7th ed.) Citation

Barbanti, P., Aurilia, C., Cevoli, S., Egeo, G., Fofi, L., Messina, R., . . . Manzo, L. (2021). Long‐term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high‐frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study. Headache, 61(9), 1351-1363. https://doi.org/10.1111/head.14194

Chicago Style (17th ed.) Citation

Barbanti, Piero, et al. "Long‐term (48 weeks) Effectiveness, Safety, and Tolerability of Erenumab in the Prevention of High‐frequency Episodic and Chronic Migraine in a Real World: Results of the EARLY 2 Study." Headache 61, no. 9 (2021): 1351-1363. https://doi.org/10.1111/head.14194.

MLA (9th ed.) Citation

Barbanti, Piero, et al. "Long‐term (48 weeks) Effectiveness, Safety, and Tolerability of Erenumab in the Prevention of High‐frequency Episodic and Chronic Migraine in a Real World: Results of the EARLY 2 Study." Headache, vol. 61, no. 9, 2021, pp. 1351-1363, https://doi.org/10.1111/head.14194.